Skip to main content
OpenTrials
Completed

NCT Number: NCT00589797

Activ-L™ Artificial Disc Treatment of Degenerative Disc Disease in the Treatment of Degenerative Disc Disease

The purpose of this study is to learn whether an investigational device called the Activ-L Artificial Disc is safe and effective in the treatment of degenerative disc disease of the lower (lumbar) spine.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Scripps Memorial Hospital La Jolla, La Jolla, California, United States

Loading trial locations.

About this study

The objective of this clinical study is to evaluate the safety and effectiveness of the Activ-L Artificial Disc for treatment of single-level degenerative disc disease of the lumbar spine in patients who have been unresponsive to at least six months of prior conservative care. The hypothesis of the study is that the Activ-L Disc is non-inferior to the control (the Charité® Artificial Disc [DePuy Spine] or ProDisc-L® Total Disc Replacement [Synthes Spine]) with respect to the rate of individual subject success at 24 months. Individual subject success is a composite of effectiveness and safety.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 - 60, skeletally mature
  • Symptomatic DDD with objective evidence of lumbar DDD, with any of the following characteristics by MRI scan:
  • instability as defined by ≥ 3mm translation or ≥ 5° angulation.
  • osteophyte formation of facet joints or vertebral endplates.
  • decreased disc height of >2mm as compared to the adjacent level.
  • scarring/thickening of the ligamentum flavum, annulus fibrosis, or facet joint capsule.
  • herniated nucleus pulposus.
  • facet joint degeneration/changes.
  • vacuum phenomenon.
  • Single level symptomatic disease at L4/L5 or L5/S1.
  • six months of unsuccessful conservative treatment
  • ODI score ≥ 40/100.
  • Surgical candidate for an anterior approach to the lumbar spine.
  • Back pain at the operative level only, with or without leg pain.
  • Back pain VAS score greater than the higher of the two VAS leg pain scores.
  • VAS back pain score ≥ 40/100 mm.
  • Willing to return for follow-up visits and sign an Informed Consent and HIPAA Authorization.

Exclusion criteria

  • Previous surgery at any lumbar level, except IDET (Intradiscal Electrothermal Annuloplasty), percutaneous nucleoplasty, or microdiscectomy.
  • Chronic radiculopathy, i.e., subject complaint of unremitting pain with a predominance of leg pain symptoms greater than back pain symptoms extending over a period of at least 1 year.
  • endplate dimensions smaller than 34.5 mm in medial-lateral and/or 27 mm in the anterior-posterior direction
  • Evidence of significant, symptomatic disc degeneration at another lumbar level.
  • Preoperative remaining disc height < 3mm
  • Myelopathy.
  • Previous compression or burst fracture at the affected level.
  • Sequestered herniated nucleus pulposus with migration.
  • Mid-sagittal stenosis of <8mm (by MRI).
  • Degenerative or lytic spondylolisthesis > 3mm.
  • Spondylolysis.
  • Isthmic spondylolisthesis.
  • Lumbar scoliosis (> 11 degrees of sagittal plane deformity).
  • Spinal tumor.
  • Active systemic infection or infection at the site of surgery.
  • Facet ankylosis or severe facet degeneration.
  • Continuing steroid use or prior use for more than 2 months.
  • History of allergies to any of the device components.
  • Pregnancy or planning to become pregnant within the next 2 years.
  • Morbid obesity (BMI >35).
  • Investigational drug or device use within 30 days.
  • Osteoporosis or osteopenia
  • Metabolic bone disease.
  • Leg pain with migrated sequestrum fragment.
  • History of rheumatoid arthritis, lupus, or other autoimmune disorder.
  • Ankylosing spondylitis.
  • History of HIV/AIDS or hepatitis that precludes surgery.
  • History of deep vein thrombosis, symptoms of arterial insufficiency, or thromboembolytic disease.
  • Current or recent history of illicit drug or alcohol abuse, or dependence as defined as the continued use of alcohol despite the development of social, legal, or health problems.
  • Life expectancy <5 years.
  • Chemotherapy within past 5 years or any cancer other than non-melanoma skin cancer treated with curative intent within the past 5 years.
  • Prior nephrectomy.
  • Abdominal adhesions, endometriosis, inflammatory bowel disease, Crohn's disease, diverticulitis, ulcerative colitis or other abdominal pathology that would preclude abdominal surgical approach.
  • Insulin-dependent diabetes.
  • Any degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to Parkinson's disease, ALS (amyotrophic lateral sclerosis), or multiple sclerosis.
  • History of Pelvic Inflammatory Disease.
  • Peritonitis.
  • Currently in active spinal litigation as a result of medical negligence.
  • Prisoner.
  • Psychiatric or cognitive impairment that would interfere with the subject's ability to comply with the study requirements, e.g., Alzheimer's disease.

Treatment and study plan

Activ-L Artificial Disc

Device

Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.

ProDisc-L Total Disc Replacement or Charité Artificial Disc

Device

Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.

Primary outcomes

  1. Overall Success at 24 Months Relative to Baseline

    Time frame: 24 months

    Measured by absence of treatment failure; absence or serious device related AE; maintenance or improvement of ROM at index level; maintenance or improvement of neurological status; improvement in ODI score.

  2. Device Success

    Time frame: 24 months

    Percent of subjects demonstrating no Subsequent Surgical Interventions (SSI's) at the index level (L4-L5 or L5-S1) at 24 months.

  3. Absence of Serious Device Related Adverse Events

    Time frame: 24 months

    Percent of subjects demonstrating no device related SAE's at 24 months as per the Clinical Events Committee (CEC)

  4. Range of Motion (ROM) Success

    Time frame: 24 months

    Percent of subjects demonstrating maintenance or improvement in ROM at 24 months compared to baseline

  5. Neurological Success

    Time frame: 24 months

    Percent of patients demonstrating maintenance or improvement in combined motor and sensory evaluations at 24 months compared to baseline

  6. ODI Success

    Time frame: 24 months

    Percent of subjects demonstrating an improvement of greater than or equal to 15 points at 24 months compared to baseline

Secondary outcomes

  1. VAS Success for Back and Leg Pain at Rest

    Time frame: 24 months

    Number of patients demonstrating improvement in back and leg pain at 24 months compared to baseline

  2. ODI Success Using Two Measures of Success

    Time frame: 24 months

    Number of subjects demonstrating improvement in two measures of ODI success at 24 months compared to baseline

  3. Improvement in SF-36 Scores

    Time frame: 24 months

    Number of subjects demonstrating a greater than or equal to 15% improvement in mental (MCS) and physical (PCS) component summary scores at 24 months compared to baseline

Sponsors and collaborators

Lead sponsor

Aesculap Implant Systems

Industry

Registry information

Official study title

Clinical Study to Evaluate the Safety and Effectiveness of the Aesculap Activ-L™ Artificial Disc in the Treatment of Degenerative Disc Disease

Important dates

Study start
2007
Primary completion
2012
Study completion
2017
First posted
Jan 10, 2008
Registry last updated
Dec 7, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.